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Maternal arsenic exposure and gestational
diabetes and glucose intolerance in the
New Hampshire birth cohort study
Shohreh F. Farzan1*, Anala Gossai2, Yu Chen3, Lisa Chasan-Taber4, Emily Baker5 and Margaret Karagas2
Abstract
Background: Gestational diabetes mellitus (GDM) is a major pregnancy complication with detrimental effects for
both mothers and their children. Accumulating evidence has suggested a potential role for arsenic (As) exposure in
the development of GDM, but current studies have not assessed As exposure from water, urine or toenail samples.
Methods: We investigated the association between As exposure and risk of glucose intolerance and GDM among
1151 women enrolled in the New Hampshire Birth Cohort Study. Arsenic was measured in home well water and via
biomarkers (i.e., maternal urine collected ~24–28 weeks gestation and toenail clippings collected 2 weeks
postpartum).
Results: A total of 105 (9.1 %) of women were diagnosed with glucose intolerance and 14 (1.2 %) of women were
diagnosed with GDM. A total of 10.3 % of women had water As levels above 10 μg/L, with a mean As level of 4.2.
Each 5 μg/L increase in As concentration in home well water was associated with a ~10 % increased odds of GDM
(OR: 1.1, 95 % CI 1.0, 1.2). A positive and statistically significant association also was observed between toenail As
and GDM (OR: 4.5, 95 % CI 1.2, 16.6), but not urinary arsenic (OR: 0.8, 95 % CI 0.3, 2.4). In a stratified analysis, the
association between water As and GDM and glucose intolerance was largely limited to obese women (OR: 1.7,
95 % CI 1.0, 2.8).
Conclusions: Our findings support the role of As exposure via water from private wells in the incidence of GDM
and that this association may be modified by body composition.
Keywords: Arsenic, Gestational diabetes, Glucose intolerance, Pregnancy cohort, New Hampshire
Background
Gestational diabetes mellitus (GDM), the onset or first
recognition of diabetes during pregnancy, is a pregnancy
complication on the rise, with reported increases of
nearly 50 % in the US from 1990 to 2009 [1]. The
Centers for Disease Control estimated that glucose in-
tolerance affects approximately 9.2 % of pregnancies in
the United States annually [2]. Women who develop GDM
are at higher risk for birth and delivery complications,
including infant macrosomia, neonatal hypoglycemia, and
cesarean delivery [3, 4]. Further, later life risks for both
mothers and their children have been documented.
Women who develop GDM have nearly a 7-fold increased
risk of type 2 diabetes in the decade after delivery and
children born to mothers with GDM are also more likely
to develop glucose intolerance and cardiometabolic disease
later in life [5–9].
While the rise in GDM is likely due to a number of
causes, exposure to environmental contaminants, such
as toxic metals, may be a possible contributor. Arsenic
(As) is a widespread, naturally occurring contaminant, to
which millions worldwide are exposed primarily via
contaminated water sources [10]. In our study area of
New Hampshire, USA, approximately 40 % of house-
holds rely on unregulated private water systems, of
which 10–15 % contain As levels exceeding the US EPA
maximum contaminant level of 10 μg/L [11]. While As
is most commonly known for its carcinogenic effects, it
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also has been associated with a number of deleterious
health effects including cardiovascular disease, respira-
tory disease, immune impairment and glucose intoler-
ance in adults [10]. A number of studies have explored
the link between As exposure and diabetes (reviewed in
[12–14]) and experimental studies have proposed several
mechanisms whereby As could affect β-cell function and
disrupt glucose homeostasis, including endocrine disrup-
tion, glucose uptake and transport, gluconeogenesis,
adipocyte differentiation, epigenetic effects and oxidative
stress [14, 15]. Further, studies of vulnerable popula-
tions, including pregnant women and children, suggest
they may be particularly susceptible to As’s harmful
effects [16–20].
Although few epidemiological studies have examined As
exposure and GDM, data are beginning to emerge on the
potential role for As in the development of impaired gesta-
tional glucose control [21–23]. Specifically, only three prior
studies have examined the association between As and
GDM, and of these, two were limited in that they relied
solely on postpartum As exposure assessments. Here in
our current study, we assessed the relationship between
GDM and As levels in three different matrices (water, urine
and toenails), which together provide a robust combination
of both short- and long-term exposure measures. For
example, toenail As is a useful biomarker for determining
prolonged exposure to inorganic As, as its affinity for kera-
tin’s sulfhydryl groups causes As to accumulate in nails.
Given the slow growth rate of toenails, toenail clippings
can reflect an exposure window approximately 6 to
12 months prior to collection [24]. Therefore, toenail sam-
ples that collected from recently postpartum mothers can
be thought to represent As exposure early in pregnancy.
Lastly, none of the prior studies evaluated the potential of
effect modification by pre-pregnancy body mass index
(BMI). A number of recent studies have indicated that pre-
pregnancy obesity may put women at a higher risk of
developing complications during their pregnancy, includ-
ing GDM [25–28]. Therefore, we evaluated the association
between water, urinary, and toenail As and risk of GDM
and glucose intolerance among women enrolled in the
New Hampshire Birth Cohort Study, and whether this
association was modified by pre-pregnancy BMI.
Methods
The New Hampshire birth cohort
The New Hampshire Birth Cohort is an ongoing study
and starting in January 2009, we began recruiting 18–45
year old pregnant women receiving prenatal care at study
clinics, as previously described [29]. Women were en-
rolled at 24–28 weeks gestation if they reported using
water from a private well at their residence since their last
menstrual period and were not planning to move prior to
delivery. Only singleton births are included in the study.
Medical record review and glucose testing
Participants completed a detailed medical history and
lifestyle questionnaire upon enrollment and a follow-up
questionnaire at 2 weeks postpartum to obtain updated
information about changes in key exposures and pre-
natal complications. After delivery, participants’ medical
records were reviewed to abstract health information,
including glucose challenge test (GCT) results, oral glu-
cose tolerance test (OGTT) results, diagnoses of GDM,
hypertension, pre-eclampsia and eclampsia. Other clin-
ical information was recorded to verify self-reported
medical and reproductive history.
The GCT is typically administered to pregnant women
between 24 and 28 weeks gestation to screen for GDM.
The patient is given a standard solution containing 50 g
of glucose to drink and after 1 h, a blood sample is
obtained to test for blood glucose. If GCT results indi-
cate possible glucose intolerance (i.e. a blood glucose
level of 120 to 140 mg/dL is considered borderline, 140
to <200 mg/dL is considered a positive result and above
200 mg/dL is considered a high positive result (based
upon the recommendations of the American College of
Obstetricians and Gynecologists), then an OGTT is typ-
ically performed to confirm a GDM diagnosis [30, 31].
In cases where the GCT indicates a high positive result
(>200 mg/dL), the physician typically will make the diag-
nosis of GDM without performing the additional OGTT.
The OGTT is a diagnostic test performed to confirm
GCT results. The patient provides a baseline pre-test
blood sample, and then drinks a standard solution con-
taining 100 g of glucose. Blood samples are collected at
timed intervals of 1, 2, and 3 h, at which blood glucose
is monitored and given a positive or negative score based
on the expected rate of clearance at each timepoint,
based on the diagnostic guidelines of the American
Diabetes Association [30, 32].
Based on results of GCT and OGTT testing, we cate-
gorized women as normal, glucose intolerant or GDM.
Specifically, women were classified with glucose intoler-
ance if they had either: 1) a borderline (120 to <140 mg/
dL) or positive (140 to <200 mg/dL) GCT result and a
follow-up OGTT with at least one positive score, or 2) a
positive GCT result (140 to <200 mg/dL) but no follow-
up OGTT. Women were classified with GDM if they
had either 1) a positive GCT result (140 to <200 mg/dL)
and a follow-up OGTT with 2 or more positive scores
or 2) a positive GCT result (140 to <200 mg/dL) and a
physician diagnosis of GDM in the medical record or 3)
a high positive GCT result (>200 mg/dL). Women were
categorized as “normal” if they had either 1) a negative
GCT result or 2) a borderline or positive GCT result
(120 to <200 mg/dL) and subsequent follow-up OGTT
with negative scores throughout the test. This set of
classification criteria was necessary for two reasons: 1)
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in cases where a GCT result is 200 mg/dl or higher, the
physician may make the diagnosis of GDM without
performing a subsequent OGTT and 2) as there are no
clinically defined criteria for glucose intolerance, we
used the information from the GCT and OGTT to in-
vestigate those women who may have failed their initial
GCT screening and had one or more above normal glu-
cose readings during their OGTT, but may not have met
the criteria for a diagnosis of GDM. We did not reclas-
sify any women who had been physician diagnosed by
OGTT with GDM as normal or glucose intolerant. This
method resulted in mutually exclusive categories of
GDM, glucose intolerant or normal.
We also constructed a continuous GCT variable, which
reflected the 24–28 week GCT result in mg/dL, if avail-
able. Some patients underwent early and multiple testing,
thus the average of all GCT (mg/dL) results within the
24–28 week gestational age range was reported. If the
patient was not tested within the 24–28 week gestational
age range, the GCT result from the test closest to 24–28
weeks was reported. Tests that were conducted before
22.5 weeks or after 32.5 weeks were excluded.
Arsenic exposure assessment
Participants were given instructions and prepaid mailing
materials upon enrollment to collect samples of their
home tap water and return the samples to the study of-
fice, which were analyzed by inductively coupled plasma
mass spectrometry (ICP-MS) at the Dartmouth Trace
Element Analysis Core, as previously described [29].
Women provided a spot urine sample upon enrollment
at 24–28 weeks gestation, which was collected and
stored, as previously described [29]. Urine samples were
analyzed for levels of arsenite (iAsIII), arsenate (iAsV),
monomethylarsonic acid (MMA), dimethylarsinic acid
(DMA) and arsenobetaine by high-performance liquid
chromatography (HPLC) inductively coupled plasma
mass spectrometry (ICP-MS) at the University of
Arizona Hazard Identification Core [33–35]. Total urin-
ary As was calculated by summing inorganic (iAs =
iAsIII + iAsV) and organic (DMA, MMA) metabolites
[29]. Arsenobetaine, a form of As found in seafood was
excluded, as it is thought to pass through the body
unmetabolized [36]. Maternal toenail samples were col-
lected at 2 weeks postpartum. Women were asked to re-
move any nail polish, clip a normal amount of toenail
from each toe after bathing and place clippings into a
small collection envelope. Samples were washed 5 times
by sonication in a solution of Triton X-100 and acetone,
followed by deionized water and then dried before low-
pressure microwave digestion. Samples were analyzed
for trace elements using ICP-MS as previously described
for As [37]. Toenail samples collected from women in
the study weighed ~25 mg on average, while a minimum
of 1–2 mg of nail is typically needed for analysis. Arsenic
was detected in 90 % of maternal toenails and 84.4 %
of water samples. Water As detection limits ranged
0.001–0.07 μg/L. Urine samples that registered below
the As detection limit (ranging from 0.10 to 0.15 μg/
L for individual urine species; 0.5, 16.8, and 36.6 % of
the study population were below the detection limit
for DMA, MMA and iAs, respectively) were assigned a
value equal to the detection limit divided by the square
root of two. Approximately 56 % of women had detectable
levels of all metabolites. As secondary exposure measures,
we constructed primary (PMI) and secondary methylation
indices (SMI) from ratios of MMA to iAs and DMA to
MMA in urine, respectively, as these are considered indi-
cators of methylation capacity that may impact individual
variability in health effects of As exposure [38].
Statistical analysis
We confined our analysis to women without a history of
diabetes and who had one or more exposure measure-
ments for As in well water, toenail clippings, and/or urine.
Arsenic exposure variables were modeled as continuous
variables and were untransformed, with the exception of
toenail As, for which natural log-transformation was ne-
cessary for model convergence. First, we used multinomial
logistic regression models, adjusted for potential con-
founders, to test the association between As exposure
variables (water As, ln-toenail As, urinary As) and a 3-
level outcome variable of GDM, glucose intolerance, and
normal blood glucose, to distinguish between levels of dis-
ease severity. Next, we used logistic regression models,
adjusted for potential confounders, to test the relation
between As exposure variables (each modeled separately)
and either glucose intolerance only or GDM only in order
to investigate the independent associations for each out-
come. Then, we used logistic regression models, adjusted
for potential confounders, to test the relation between As
exposure variables (each modeled separately) and with a
combined outcome variable, where both glucose intoler-
ance and GDM cases were pooled, in order to examine all
cases of any glucose control impairment together. Lastly,
we also used linear regression models, adjusted for poten-
tial confounders, to test the relation between As exposure
variables and continuous GCT values.
We examined the As exposures of interest with GDM
outcomes in both unadjusted and minimally adjusted
models (enrollment age and educational attainment)
(Additional file 1: Table S1). Our final models were
adjusted for covariates available from medical records
and questionnaires that could potentially influence glu-
cose control based on a priori considerations, including
age at enrollment, pre-pregnancy body mass index
(BMI), pregnancy weight gain, smoking during preg-
nancy, secondhand smoke exposure during pregnancy,
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educational attainment, and gestational week of glucose
testing. In models where urinary arsenic was the expos-
ure of interest, we additionally adjusted for urinary cre-
atinine in our analyses.
Potential effect modification by pre-pregnancy BMI
was evaluated by inspection of stratum specific odds
ratios and by including a multiplicative interaction term
in the multivariable logistic regression models and asses-
sing its statistical significance at p < 0.05 using likelihood
ratio chi-square tests. In stratified analyses, maternal
pre-pregnancy BMI was categorized by World Health
Organization standards [39].
Results
As of May 1, 2016, a total of 1473 participants had
enrolled in the NHBCS and of those, 1307 had GCT
and/or OGTT results available in their medical record.
An additional 30 women were excluded due to a history
of diabetes. Of those, 1151 women had at least one avail-
able As exposure measurement for either urine, toenails
and/or water at the time of analysis, resulting in final
sample sizes of 853 (water As), 778 (toenail As) and
1049 (urinary As).
A total of 14 (1.2 %) women were diagnosed with GDM
and 105 (9.1 %) women were categorized as glucose intoler-
ant. The mean (SD) GCT level was 110.7 (26.3) mg/dL.
Nearly 1 in every 10 households (88 of 853 available
samples; 10.3 %) tested in this study had water As levels
above EPA maximum contaminant limit of 10 μg/L, with
a mean As level of 4.2 μg/L (range: 0.001–189.3 μg/L).
Women in this sample had a mean toenail As concen-
tration of 0.1 μg/g, with values ranging from 0.001 to
0.7 μg/g and a mean urinary As concentration of
5.9 μg/L with values ranging from 0.2 to 288.5 μg/L
(Table 1). Water As (above 1 μg/L) was positively cor-
related with both toenail As (r = 0.61, p < 0.0001) and
urinary As (r = 0.35, p < 0.0001), but water As below
1 μg/L was not (toenail As r = 0.08, p = 0.11 and urinary
As r = −0.01, p = 0.81). Urinary As also correlated with
toenail As (r = 0.18, p < 0.0001). Statistically significant
differences between women with normal glucose con-
trol and those with either glucose tolerance or GDM
were observed for enrollment age, race, pre-pregnancy
BMI and weight gain during pregnancy (Table 1).
Using multinomial regression models adjusted for
enrollment age, education, smoking during pregnancy,
secondhand smoke exposure during pregnancy, pre-
pregnancy BMI, weight gain during pregnancy, and gesta-
tional week of glucose testing, we observed a borderline
statistically significant association between water As and
GDM, with a 10 % increased risk of GDM associated with
each 5 μg/L increase in water As (OR: 1.1, 95 % CI: 1.0,
1.2) (Table 2). We also observed a statistically significant
positive association between toenail As and GDM, with
each 100 % increase in toenail As associated with nearly a
four-fold increased risk of GDM (OR: 4.5, 95 % CI: 1.2,
16.6) (Table 2), but with wide confidence intervals. We
did not observe statistically significant associations urinary
As and GDM (OR: 0.8, 95 % CI: 0.3, 2.4) nor between any
of the arsenic measures and risk of glucose intolerance
(Table 2). We also examined the association of As expos-
ure with the each of the outcomes individually (glucose in-
tolerance only or GDM only; Additional file 1: Table S2).
These results mirrored those observed with the multi-
nomial models, such that for each 5 μg/L increase in water
As we observed a marginally significant increase risk of
GDM only (OR: 1.1, 95 % CI: 1.0, 1.2). We also found that
each 100 % increase in toenail As was associated with a
statistically significant increased risk of GDM only (OR:
4.5, 95 % CI: 1.3, 16.2), but with wide confidence intervals
(Additional file 1: Table S2). We did not observe any rela-
tionship between of any of the As exposure variables and
glucose intolerance only, nor did we observe an associ-
ation of any measure of As exposure with the pooled out-
come of any glucose intolerance (i.e. combined glucose
intolerance and GDM) (Table 2). Furthermore, we did not
observe any relationship between of any of the As expos-
ure variables and GCT, when GCT results were used as a
continuous measure (Additional file 1: Table S3).
Next, we evaluated whether pre-pregnancy BMI modi-
fied the association between As and glucose intolerance
(Table 3). Among women who were categorized as obese
(BMI ≥ 30 kg/m2), for each 5 μg/L increase in water As
we observed a statistically significant increase risk of
GDM or glucose intolerance (OR: 1.7, 95 % CI: 1.0, 2.8;
p-value = 0.04) (Table 3). In contrast, there were no asso-
ciations between As and GDM/glucose intolerance
among women who were underweight to normal or
overweight. We tested for interaction between water As
and maternal BMI, using a multiplicative interaction
term in our model, but this did not reach statistical
significance (p-interaction = 0.08).
Lastly, we performed additional sensitivity analyses to
test the relationship between arsenic exposure and
GDM, among those with water As above and below the
10 μg/L MCL. When we restricted our analyses to the
only those individuals with water As below 10 μg/L, we
found that the association between water As and GDM
remained positive (OR: 1.4, 95 % CI: 0.2–9.4), albeit
with wide confidence intervals. Similarly, when we ex-
amined the relation between toenail As and GDM
among those with water As below 10 μg/L, we see a
similar positive trend (GDM OR: 2.6, 95 % CI: 0.6–11.4;
Intolerant OR: 0.9, 95 % CI: 0.6–1.3), but also with wide
confidence intervals. We were unable to test only those
with water As above 10 μg/L, due to limited sample
size and few cases of GDM or glucose intolerance with
water As above 10 μg/L.
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Discussion
In this prospective study of US women, we evaluated the
associations between multiple markers of As exposure
and glucose intolerance and GDM during pregnancy.
We observed a positive statistically significant associ-
ation between toenail As and GDM. We also found that
each 5ug/L increase in As in a woman’s household well
water was related to nearly a 10 % greater risk of GDM,
which was consistent with our findings for toenail As.
There was no evidence that higher levels of maternal
urinary As was related to greater risks of either glucose
intolerance during pregnancy or GDM. We only ob-
served an association for As exposure and GDM, but did
not find evidence of an association with glucose intoler-
ance. Although one may assume that these are two con-
ditions on the same spectrum of metabolic dysfunction,
it is possible that there may be differences in underlying
pathophysiology, which could be differentially impacted by
As exposure. Further analyses stratified by pre-pregnancy
BMI indicate that these associations may be primarily
limited to obese women, who made up approximately 37 %
of total combined cases of glucose intolerance or GDM.
Our findings are consistent with those of prior studies
that have observed a relationship between As and glu-
cose control during pregnancy. In one of the first studies
to examine the role of As in glucose tolerance, Ettinger
et al. conducted a cross-sectional study of 532 women
living near the Tar Creek Superfund site in Oklahoma.
The authors found that the highest quartile of maternal
blood As at delivery was associated with impaired glu-
cose tolerance at 24–28 weeks of gestation (OR: 2.8,
95 % CI: 1.1, 6.9) [21]. They also reported that hair As, a
long-term biomarker that is similar to toenail As, was
associated with a 4-fold increased odds of impaired glu-
cose tolerance (OR: 4.2, 95 % CI: 0.7–23.9), although this
was not statistically significant [21]. These results were
similar to our observation of an association between toe-
nail As and GDM. In a large longitudinal study of 1274
Canadian women, Shapiro et al. observed a positive rela-
tionship between the highest quartile of first trimester
blood As and GDM (OR: 3.7, 95 % CI: 1.4, 9.6), as well
as with combined GDM and glucose intolerance (OR:
1.9, 95 % CI: 1.1, 3.5) [22]. A nested case–control study
within pregnancy cohort of Chinese women compared
metals, including As, in meconium samples from infants
born to healthy mothers (n = 190) or mothers with
GDM (n = 137). Meconium As was dose-dependently as-
sociated with maternal GDM (OR: 3.3, 95 % CI: 1.2, 8.7;
OR: 3.4, 95 % CI: 1.3, 8.8; and OR: 5.3, 95 % CI: 2.0,
13.9, for the 2nd, 3rd and 4th quartiles of meconium As,
respectively) [23].
The various As biomarkers have a number of strengths
and limitations, which impact how the data are inter-
preted. For example, water As levels are a good surro-
gate for As exposure where the primary source of
exposure is water and where individual water intake
levels are known, but will underestimate exposure levels
among populations with high inorganic As intake from
foods, such as rice [29, 40]. Arsenic measured in blood
tends to have a very short half-life, which may make it
more prone to exposure misclassification than more
stable, long-term measures [41]. Blood As measurements
are also typically not speciated for As metabolites and
Table 1 Characteristics for 1151 pregnant women enrolled in
the New Hampshire Birth Cohort Study with at least one
exposure measurement
N (%) or mean (SD)
Variable Normal
(n = 1032)
Glucose Intolerant
& GDM
(n = 119)
p-value**
Maternal age at enrollment 30.9 (4.9) 32.2 0.02
Race
White 1020 (98.8) 113 (95.0) 0.01
Educational attainment
Less than college 304 (32.9) 32 (32.4)
College graduate 362 (39.2) 43 (43.4)
Any post-graduate school 258 (27.9) 24 (24.2) 0.48
Relationship status
Married 787 (85.2) 90 (90.9)
Single, separated,
divorced
137 (14.8) 9 (9.1) 0.28
Pre-pregnancy BMI* 25.7 (5.6) 28.2 (6.3) <0.0001
Weight gain during
pregnancy*
35.3 (14.5) 28.9 (16.3) <0.0001
Parity*
Nulliparous 428 (41.5) 48 (40.3)
1 to 2 530 (51.4) 61 (51.3)
3+ 74 (7.2) 10 (8.4) 0.53
Smoke Exposure
Ever smoked during
pregnancy
61 (6.5) 4 (4.0) 0.67
Exposed to secondhand
smoke during pregnancy
131 (13.9) 14 (14.0) 0.77
Arsenic Exposure
Well water arsenic (μg/L) 4.2 (13.2); range
0.001–189.3
4.1 (13.0); range
0.005–96.5
0.83
Well water ≥10 μg/L MCL 81 (10.7) 7 (7.5) 0.48
Urinary arsenic (μg/L) 5.8 (12.4); range
0.2–288.5
6.5 (15.5); range
0.6–157.3
0.10
Toenail arsenic (μg/g) 0.1 (0.1); range
0.001–0.7
0.1 (0.1); range
0.009–0.7
0.50
Glucose Control
Glucose Intolerant 0 105
Gestational diabetes 0 14
*Missing (n)- pre-pregnancy BMI (41), weight gain (42), smoking (110),
secondhand smoke (108), school level (128), relationship status (128),
urinary arsenic (102), well water arsenic (298), toenail arsenic (373).
**Compared using the X2 test or Fisher’s exact test (categorical variables)
and Wilcoxon rank sum test (for continuous variables)
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total blood As includes inorganic and organic species
that may vary in their toxicity. Thus, blood As measures
may overestimate exposure in some individuals who
consume fish and seafood, primary sources for organoar-
senicals, which are thought to pass through the body
unmetabolized and may or may not contribute to overall
toxicity [36]. However, in populations that are chronic-
ally exposed to As, blood As can reach a steady-state
and reflect long-term exposure levels [42]. Urinary As is
a short-term biomarker of both inorganic and organic
As species and generally reflects exposure from both
water and food sources over the past 2–3 days [42],
although studies have found that urinary As concentra-
tions over a period of time remain within a relatively
constant range in adults [43, 44]. Toenail As, like hair
As used in previous studies, is a biomarker of inorganic
As exposure that approximates a window of exposure
~6–12 months prior to sample collection, providing a
more long-term exposure measure than urine [24]. For
example, in the case of our current study, toenail sam-
ples collected from mothers at 2 weeks postpartum can
be thought to represent a period of exposure in early
pregnancy. We only observed associations for toenail As
with GDM and marginal associations with water As.
Given that water As comprised only of inorganic As and
toenails primarily reflect inorganic As levels, it is pos-
sible that differences in the associations between the
three As biomarkers in our study with GDM may sug-
gest that inorganic As, in contrast to organic As, may be
more important in the development of GDM. However,
we cannot distinguish between intake of organic As and
metabolism of inorganic As to organic As metabolites in
urine samples and when we examined urinary levels of
inorganic versus organic As species, neither were related
to GDM or glucose intolerance alone (data not shown).
It is possible that there is additional residual confound-
ing that we may not have accounted for in this context
and we may not have been able to detect an effect with
urinary As due to the fact that only 56 % of individuals
had detectable levels of all urinary As species. Further-
more, urinary As levels may not be a reliable indicator
of exposure when examining a metabolic disease that
may impact urinary dilution.
Several studies have suggested that women with
greater pre-pregnancy BMI may be at higher risk of
developing GDM, but to our knowledge, our study is the
first to explore maternal pre-pregnancy BMI as a poten-
tial effect modifier of the relationship between As and
GDM [26–28]. In an analysis of combined GDM and
glucose intolerance, our results suggested that As expos-
ure and glucose intolerance outcomes may be more
strongly related among obese women, although this was
of borderline statistical significance. Further analyses of
GDM or glucose intolerance as individual outcomes
were limited by our sample size.
The question of whether environmental contaminants
may impact GDM risk is one of critical importance. In
addition to possible associations with As, exposure to air
pollutants, cadmium and chromium have also been associ-
ated with GDM and glucose intolerance [45–47]. GDM is
the most common medical complication of pregnancy and
places women at a higher risk of caesarean section, birth
injuries due to infant macrosomia, and neonatal mortality
[48]. Maternal hyperglycemia increases fetal insulin levels
Table 3 Relation between water arsenic concentrations† and combined endpoint of GDM or glucose intolerance (pooled), stratified
by pre-pregnancy BMI
Pre-pregnancy BMI Non-cases Cases % Cases‡ OR (95 % CI)
Underweight to Normal (<25) 388 32 8.2 0.9 (0.8, 1.2)
Overweight (25–29.99) 157 25 15.9 1.0 (0.8, 1.2)
Obese (≥30) 118 33 28.0 1.7 (1.0, 2.8)**
Combined outcome variable was coded a dichotomous variable (0 = normal or 1 = GDM or intolerant). Models were adjusted for enrollment age, education,
smoking during pregnancy, secondhand smoke exposure during pregnancy, weight gain and gestational week of glucose testing. †Per 5 μg/L increase in water
As; ‡Represents the percent of total cases within each BMI category; **p <0.05
Table 2 Relation between arsenic exposure and glucose tolerance status
Glucose Intoleranta Gestational Diabetes Mellitusa Combined Glucose Intolerant and GDMb
Arsenic exposure Non-cases Cases OR (95 % CI) Cases OR (95 % CI) Cases OR (95 % CI)
Water As† 663 79 1.0 (0.9, 1.1) 11 1.1 (1.0, 1.2)* 90 1.0 (0.9, 1.1)
Urinary As† 582 61 1.0 (1.0, 1.1) 9 0.8 (0.3, 2.4) 70 1.0 (1.0, 1.1)
Toenail As‡ 616 62 0.9 (0.6, 1.3) 7 4.5 (1.2, 16.6)** 69 0.9 (0.7, 1.3)
aOutcome variable is a 3-level variable (0 = normal, 1 = intolerant, 2 = GDM), modeled using multinomial regression; bcombined glucose intolerance and GDM is
modeled with logistic regression using a dichotomous variable (0 = normal or 1 = glucose intolerant and GDM). Models were adjusted for enrollment age,
education, smoking during pregnancy, secondhand smoke exposure during pregnancy, pre-pregnancy BMI, weight gain and gestational week of glucose testing.
Additional adjustment for urinary creatinine was included in the urinary As model only. †Per 5 μg/L increase in water or urinary As; ‡per 100 % increase in toenail
As; *0.1 < p < 0.05; **p <0.05
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and stimulates growth, leading to higher birth weights
among children born to mothers with GDM [48, 49].
Among the long-term consequences of GDM, evidence
suggests that mothers who experience GDM are more
likely to develop Type II diabetes mellitus later in life [5].
Children born to mothers with GDM exhibit impaired fetal
endothelial function and growing evidence indicates that
these children have greater risks of developing cardiometa-
bolic disease, obesity and Type II diabetes [6–9, 50, 51].
While further investigation of As’s role in development of
GDM is needed, increases in the risk of GDM could im-
pact long-term health of both mothers and their children.
A major strength of our study is the use of multiple
As exposure markers that reflect different types of
exposure at various points within pregnancy, as well as
the ability to adjust for detailed medical history and
sociodemographic information. Our study had limited
statistical power to observe some associations with
GDM. Although nearly 10 % met criteria for glucose
intolerance, only 1 % of women were diagnosed with
GDM, in contrast to US national GDM prevalence esti-
mates, which range from ~3 to 10 % of all pregnancies
[2], although these estimates may vary based upon pre-
natal glucose screening thresholds [31]. However, in
spite of this limitation we observed a statistically signifi-
cant association between toenail As and GDM and a
marginal association for home well water As and risk of
GDM. Further larger investigations are needed and may
consider contribution of other risk factors such as diet,
physical activity and variant polymorphisms in genes
related to glucose control, which may increase the risk
of type II diabetes [52], as well as poor glucose regula-
tion during pregnancy.
Conclusions
Our findings support a potential role for As exposure
via water sources in the development of GDM, but not
glucose intolerance. Given the relatively high prevalence
of exposure to As through water and food sources, even
small exposure-related increases in the risk of GDM
could have long-term health ramifications for both
mothers and their children. Further characterization of
modifiable environmental risk factors could significantly
improve the long-term health of both pregnant women
and their children.
Additional file
Additional file 1: Supplementary Tables. (DOCX 18 kb)
Abbreviations
As: Arsenic; BMI: Body mass index; GCT: Glucose challenge test;
GDM: Gestational diabetes mellitus; OGGT: Oral glucose tolerance test
Acknowledgements
Not applicable.
Funding
S.F. Farzan is supported by a NIEHS K99/R00 (R00ES024144), and the NIEHS
Superfund Research Program (P42ES007373). Y. Chen is supported by a NIH
R01 (R01ES017541), the NYU EHS center (P30ES000260) and the Columbia
University Superfund (P42ES010349). The Children’s Center for Environmental
Health and Disease Prevention Research at Dartmouth is supported by NIEHS
and USEPA grants (ES022832, RD83459901). The funding agencies that
supported this work had no role in the planning, design, or execution of this
study, nor any role in data analysis or manuscript preparation.
Availability of data and materials
As this is an ongoing cohort study, the authors do not wish to make data
publicly available at this time. However, individual requests for data will be
reviewed by the study team, with the sole aim of guarding against
inappropriate use. We will provide the requested data pending assurances
that the confidentiality of our study subjects will not be violated. Any data
provided will be stripped of specific subject identifiers.
Authors’ contributions
MRK was responsible for the conception and design of the work, as well as
oversight of data collection. SFF, YC, MRK and AG participated in the data
analysis and interpretation of the results. SFF drafted the article and all
authors provided comments and participated in the critical revision of the
article. All authors gave their final approval of this version to be published.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All participants provided written, informed consent upon enrollment. All
protocols were approved by the Dartmouth College Institutional Review
Board (Dartmouth Committee for the Protection of Human Subjects
Approval Reference #20844).
Author details
1Division of Environmental Health, Department of Preventive Medicine, Keck
School of Medicine of University of Southern California, 2001 N. Soto Street,
MC 9237, Los Angeles, CA 90089, USA. 2Department of Epidemiology, Geisel
School of Medicine at Dartmouth, Lebanon, NH, USA. 3Department of
Population Health, New York University School of Medicine, New York, NY,
USA. 4Department of Biostatistics & Epidemiology, School of Public Health &
Health Sciences, University of Massachusetts, Amherst, MA, USA.
5Department of Obstetrics and Gynecology, Geisel School of Medicine at
Dartmouth, Lebanon, NH, USA.
Received: 4 June 2016 Accepted: 29 October 2016
References
1. Martin JA, Hamilton BE, Ventura SJ, Osterman MJK, Kirmeyer S, Mathews TJ,
et al. Births: final data for 2009. In: National vital statistics reports. vol. 60: U.
S. Department of Health and Human Services Centers for Disease Control
and Prevention. 2012. p. 1–66.
2. DeSisto CL, Kim SY, Sharma AJ. Prevalence estimates of gestational diabetes
mellitus in the United States, Pregnancy Risk Assessment Monitoring System
(PRAMS), 2007–2010. Prev Chronic Dis. 2014;11:E104.
3. HAPO Study Collective Research Group. Hyperglycemia and Adverse
Pregnancy Outcome (HAPO) Study: associations with neonatal
anthropometrics. Diabetes. 2009;58(2):453–9.
4. HAPO Study Collective Research Group, Metzger BE, Lowe LP, Dyer AR,
Trimble ER, Chaovarindr U, et al. Hyperglycemia and adverse pregnancy
outcomes. N Engl J Med. 2008;358(19):1991–2002.
5. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after
gestational diabetes: a systematic review and meta-analysis. Lancet. 2009;
373(9677):1773–9.
Farzan et al. Environmental Health  (2016) 15:106 Page 7 of 8
6. Dabelea D, Mayer-Davis EJ, Lamichhane AP, D’Agostino Jr RB, Liese AD,
Vehik KS, et al. Association of intrauterine exposure to maternal diabetes
and obesity with type 2 diabetes in youth: the SEARCH Case-Control Study.
Diabetes Care. 2008;31(7):1422–6.
7. Kelstrup L, Damm P, Mathiesen ER, Hansen T, Vaag AA, Pedersen O, et al.
Insulin resistance and impaired pancreatic beta-cell function in adult
offspring of women with diabetes in pregnancy. J Clin Endocrinol Metab.
2013;98(9):3793–801.
8. Nehring I, Chmitorz A, Reulen H, von Kries R, Ensenauer R. Gestational diabetes
predicts the risk of childhood overweight and abdominal circumference
independent of maternal obesity. Diabet Med. 2013;30(12):1449–56.
9. Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in
adolescent offspring of diabetic mothers. Relationship to fetal
hyperinsulinism. Diabetes Care. 1995;18(5):611–7.
10. National Research Council. Critical aspects of EPA’s IRIS assessment of
inorganic arsenic: interim report. Washington, DC: National Research
Council; 2014.
11. Karagas MR, Stukel TA, Tosteson TD. Assessment of cancer risk and
environmental levels of arsenic in New Hampshire. Int J Hyg Environ Health.
2002;205(1-2):85–94.
12. Kuo CC, Moon K, Thayer KA, Navas-Acien A. Environmental chemicals and
type 2 diabetes: an updated systematic review of the epidemiologic
evidence. Curr Diab Rep. 2013;13(6):831–49.
13. Sung TC, Huang JW, Guo HR. Association between arsenic exposure and
diabetes: a meta-analysis. Biomed Res Int. 2015;2015:368087.
14. Maull EA, Ahsan H, Edwards J, Longnecker MP, Navas-Acien A, Pi J, et al.
Evaluation of the association between arsenic and diabetes: a National
Toxicology Program workshop review. Environ Health Perspect. 2012;
120(12):1658–70.
15. Tseng CH. The potential biological mechanisms of arsenic-induced diabetes
mellitus. Toxicol Appl Pharmacol. 2004;197(2):67–83.
16. Farzan SF, Chen Y, Wu F, Jiang J, Liu M, Baker E, et al. Blood pressure
changes in relation to arsenic exposure in a U.S. pregnancy cohort. Environ
Health Perspect. 2015;123(10):999–1006.
17. Farzan SF, Li Z, Korrick SA, Spiegelman D, Enelow R, Nadeau K, et al. Infant
infections and respiratory symptoms in relation to arsenic exposure in a U.S.
cohort. Environ Health Perspect. 2015;124(6):840–7.
18. Nadeau KC, Li Z, Farzan S, Koestler D, Robbins D, Fei DL, et al. In utero
arsenic exposure and fetal immune repertoire in a US pregnancy cohort.
Clin Immunol. 2014;155(2):188–97.
19. Rahman A, Vahter M, Ekstrom EC, Persson LA. Arsenic exposure in
pregnancy increases the risk of lower respiratory tract infection and diarrhea
during infancy in Bangladesh. Environ Health Perspect. 2011;119(5):719–24.
20. Raqib R, Ahmed S, Sultana R, Wagatsuma Y, Mondal D, Hoque AM, et al.
Effects of in utero arsenic exposure on child immunity and morbidity in
rural Bangladesh. Toxicol Lett. 2009;185(3):197–202.
21. Ettinger AS, Zota AR, Amarasiriwardena CJ, Hopkins MR, Schwartz J, Hu H,
et al. Maternal arsenic exposure and impaired glucose tolerance during
pregnancy. Environ Health Perspect. 2009;117(7):1059–64.
22. Shapiro GD, Dodds L, Arbuckle TE, Ashley-Martin J, Fraser W, Fisher M, et al.
Exposure to phthalates, bisphenol A and metals in pregnancy and the
association with impaired glucose tolerance and gestational diabetes
mellitus: The MIREC study. Environ Int. 2015;83:63–71.
23. Peng S, Liu L, Zhang X, Heinrich J, Zhang J, Schramm KW, et al. A nested
case-control study indicating heavy metal residues in meconium associate
with maternal gestational diabetes mellitus risk. Environ Health. 2015;14:19.
24. Karagas MR, Tosteson TD, Blum J, Klaue B, Weiss JE, Stannard V, et al.
Measurement of low levels of arsenic exposure: a comparison of water and
toenail concentrations. Am J Epidemiol. 2000;152(1):84–90.
25. Whiteman VE, Salemi JL, Mejia De Grubb MC, Ashley Cain M, Mogos MF, Zoorob
RJ, et al. Additive effects of Pre-pregnancy body mass index and gestational
diabetes on health outcomes and costs. Obesity. 2015;23(11):2299–308.
26. Shin D, Song WO. Prepregnancy body mass index is an independent risk
factor for gestational hypertension, gestational diabetes, preterm labor, and
small- and large-for-gestational-age infants. J Matern Fetal Neonatal Med.
2015;28(14):1679–86.
27. Liu L, Hong Z, Zhang L. Associations of prepregnancy body mass index and
gestational weight gain with pregnancy outcomes in nulliparous women
delivering single live babies. Sci Rep. 2015;5:12863.
28. Schummers L, Hutcheon JA, Bodnar LM, Lieberman E, Himes KP. Risk of
adverse pregnancy outcomes by prepregnancy body mass index: a
population-based study to inform prepregnancy weight loss counseling.
Obstet Gynecol. 2015;125(1):133–43.
29. Gilbert-Diamond D, Cottingham KL, Gruber JF, Punshon T, Sayarath V,
Gandolfi AJ, et al. Rice consumption contributes to arsenic exposure in US
women. Proc Natl Acad Sci U S A. 2011;108(51):20656–60.
30. American Diabetes Association. Management of diabetes in pregnancy.
Diabetes Care. 2016;39(Supplement 1):S94–8.
31. Committee on Practice. Practice bulletin no. 137: gestational diabetes
mellitus. Obstet Gynecol. 2013;122(2 Pt 1):406–16.
32. American Diabetes Association. Standards of medical care in
diabetes—2014. Diabetes Care. 2014;37(Supplement 1):S14–80.
33. Le XC, Lu XF, Ma MS, Cullen WR, Aposhian HV, Zheng BS. Speciation of key
arsenic metabolic intermediates in human urine. Anal Chem. 2000;72(21):
5172–7.
34. Wei HY, Brockhoff-Schwegel CA, Creed JT. A comparison of urinary arsenic
speciation via direct nebulization and on-line photo-oxidation-hydride
generation with IC separation and ICP-MS detection. J Anal At Spectrom.
2001;16(1):12–9.
35. Larsen EH, Pritzl G, Hansen SH. Speciation of 8 arsenic compounds in
human urine by high-performance liquid-chromatography with inductively-
coupled plasma-mass spectrometric detection using antimonate for internal
chromatographic standardization. J Anal At Spectrom. 1993;8(4):557–63.
36. Tseng CH. A review on environmental factors regulating arsenic
methylation in humans. Toxicol Appl Pharmacol. 2009;235(3):338–50.
37. Davis MA, Li Z, Gilbert-Diamond D, Mackenzie TA, Cottingham KL, Jackson
BP, et al. Infant toenails as a biomarker of in utero arsenic exposure. J Expos
Sci Environ Epidemiol. 2014;24(5):467–73.
38. Chen Y, Wu F, Liu M, Parvez F, Slavkovich V, Eunus M, et al. A prospective study
of arsenic exposure, arsenic methylation capacity, and risk of cardiovascular
disease in Bangladesh. Environ Health Perspect. 2013;121(7):832–8.
39. World Health Organization. Global Database on Body Mass Index. 2016. http://
www.euro.who.int/en/health-topics/disease-prevention/nutrition/data-and-
statistics. Accessed 08 Mar 2016
40. Navas-Acien A, Nachman KE. Public health responses to arsenic in rice and
other foods. JAMA Intern Med. 2013;173(15):1395–6.
41. Hall M, Chen Y, Ahsan H, Slavkovich V, van Geen A, Parvez F, et al. Blood
arsenic as a biomarker of arsenic exposure: results from a prospective study.
Toxicology. 2006;225(2-3):225–33.
42. National Research Council. Arsenic in drinking water. Washington, DC:
National Academies Press; 1999.
43. Ahmed S, Mahabbat-e Khoda S, Rekha RS, Gardner RM, Ameer SS, Moore S,
et al. Arsenic-associated oxidative stress, inflammation, and immune
disruption in human placenta and cord blood. Environ Health Perspect.
2011;119(2):258–64.
44. Gamble MV, Liu X, Ahsan H, Pilsner JR, Ilievski V, Slavkovich V, et al. Folate
and arsenic metabolism: a double-blind, placebo-controlled folic acid-
supplementation trial in Bangladesh. Am J Clin Nutr. 2006;84(5):1093–101.
45. Fleisch AF, Gold DR, Rifas-Shiman SL, Koutrakis P, Schwartz JD, Kloog I, et al.
Air pollution exposure and abnormal glucose tolerance during pregnancy:
the project Viva cohort. Environ Health Perspect. 2014;122(4):378–83.
46. Hu H, Ha S, Henderson BH, Warner TD, Roth J, Kan H, et al. Association of
atmospheric particulate matter and ozone with gestational diabetes
mellitus. Environ Health Perspect. 2015;123(9):853–9.
47. Robledo CA, Mendola P, Yeung E, Mannisto T, Sundaram R, Liu D, et al.
Preconception and early pregnancy air pollution exposures and risk of
gestational diabetes mellitus. Environ Res. 2015;137:316–22.
48. Hay Jr WW. Care of the infant of the diabetic mother. Curr Diab Rep. 2012;
12(1):4–15.
49. Silverman BL, Rizzo T, Green OC, Cho NH, Winter RJ, Ogata ES, et al. Long-
term prospective evaluation of offspring of diabetic mothers. Diabetes.
1991;40 Suppl 2:121–5.
50. Sultan SA, Liu W, Peng Y, Roberts W, Whitelaw D, Graham AM. The role of
maternal gestational diabetes in inducing fetal endothelial dysfunction. J
Cell Physiol. 2015;230(11):2695–705.
51. West NA, Crume TL, Maligie MA, Dabelea D. Cardiovascular risk factors in
children exposed to maternal diabetes in utero. Diabetologia. 2011;54(3):504–7.
52. Pontiroli AE, Capra F, Veglia F, Ferrari M, Xiang KS, Bell GI, et al. Genetic
contribution of polymorphism of the GLUT1 and GLUT4 genes to the
susceptibility to type 2 (non-insulin-dependent) diabetes mellitus in
different populations. Acta Diabetol. 1996;33(3):193–7.
Farzan et al. Environmental Health  (2016) 15:106 Page 8 of 8
